Rhythm Pharmaceuticals at ObesityWeek 2026
Nov 14–17, 2026 National Harbor, MD ~4.4k attendees Website
Rhythm Pharmaceuticals brings 2 presentations to ObesityWeek 2026 in National Harbor, and exhibits at Booth 401. Its sessions focus on acquired hypothalamic obesity as a diagnosis that can be missed. They set out an international expert consensus on diagnostic criteria in children and adults.
| Organization | ObesityWeek 2026 Attendance |
|---|---|
Rhythm Pharmaceuticals Boston, MA | ◆Silver Sponsor |
Biopharmaceutical company developing precision medicines for rare neuroendocrine diseases, including acquired hypothalamic obesity. | Booth Exhibiting at Booth 401 Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Talk Sun Nov 15 12:00pm–1:00pm Defining Acquired Hypothalamic Obesity: An International Expert Consensus on Diagnostic Criteria in Children and Adults Unveils 2026 international consensus criteria for diagnosing acquired hypothalamic obesity, a rare form caused by hypothalamic damage, in children and adults. Policy and public health Talk Mon Nov 16 7:30am–8:30am The Obesity Diagnosis You May Be Missing: Acquired Hypothalamic Obesity Case-based guide to spotting obesity caused by hypothalamic damage from tumors, brain injury or stroke, with Phase 3 results for a targeted drug. Clinical obesity care and professional practicePediatric and adolescent obesityObesity pharmacotherapy and drug developmentNeuroscience of appetite and eatingInterventional and clinical studies |
Find decision makers at Rhythm Pharmaceuticals
Tell us what you sell and we’ll find the people at Rhythm Pharmaceuticals most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by The Obesity Society (TOS), ObesityWeek® or the American Society for Metabolic and Bariatric Surgery (ASMBS). Submit a correction